9.80
0.07 (0.72%)
Previous Close | 9.73 |
Open | 9.68 |
Volume | 4,077,528 |
Avg. Volume (3M) | 2,589,818 |
Market Cap | 2,928,299,008 |
Price / Earnings (Forward) | 62.89 |
Price / Sales | 6.03 |
Price / Book | 16.43 |
52 Weeks Range | |
Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
Profit Margin | -21.21% |
Operating Margin (TTM) | 17.53% |
Diluted EPS (TTM) | -0.330 |
Quarterly Revenue Growth (YOY) | 36.70% |
Total Debt/Equity (MRQ) | 248.66% |
Current Ratio (MRQ) | 3.15 |
Operating Cash Flow (TTM) | -26.52 M |
Levered Free Cash Flow (TTM) | -10.72 M |
Return on Assets (TTM) | 1.16% |
Return on Equity (TTM) | -67.09% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Mixed | |
Stock | Amicus Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
Analyst Consensus | 5.0 |
Insider Activity | NA |
Price Volatility | -1.0 |
Technical Moving Averages | -1.0 |
Technical Oscillators | 2.0 |
Average | 1.25 |
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Growth |
% Held by Insiders | 0.77% |
% Held by Institutions | 103.52% |
52 Weeks Range | ||
Price Target Range | ||
High | 21.00 (Cantor Fitzgerald, 114.29%) | Buy |
Median | 16.50 (68.37%) | |
Low | 12.00 (Morgan Stanley, 22.45%) | Hold |
Average | 16.50 (68.37%) | |
Total | 1 Buy, 1 Hold | |
Avg. Price @ Call | 9.32 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Cantor Fitzgerald | 15 Jan 2025 | 21.00 (114.29%) | Buy | 9.27 |
Morgan Stanley | 13 Dec 2024 | 12.00 (22.45%) | Hold | 9.36 |
No data within this time range.
Date | Type | Details |
---|---|---|
10 Feb 2025 | Announcement | Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025 |
03 Feb 2025 | Announcement | Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025 |
12 Jan 2025 | Announcement | Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook |
02 Jan 2025 | Announcement | Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |